RE:RE:RE:RE:RE:Impacted by end of agrements in LATAM- is this only Gilead ?curiousj wrote: keep in mind that Exelon is a branded generic and the focus with the new head of branded generics at Knight will be to right size the business and refocus on the right categories and brands... also branded generics from Argentina may not be sold across Latam, so figuring out the long-term plan still remains, and similarly the plan for exelon
Absolutely - this is exactly how Samira/Goodman build a powerhouse in ROW.
Selling in LATAM will always be evaluated and new strategies set if need be.
Where to take Exelon will be discussed - rights in 15 or 16 countries (if I recall correctly).
Where to manufacture will also come up - could Chile be added as a future manufacturing base?
Might make an acquisition in Chile (or similar) more likely if cost base is even lower there.
Exelon is likely the first big test between GUD and Big Pharma - others to follow in the future.
As pharma gets hit badly on the markets (opioids and general market conditions), opportunities globally are surely opening up for GUD. This little pause in growth is normal and you can see it at various points in PLB's 19 years. Also followed up by nice growth periods after years where there's pause.
Amortizations will be high and will continue - that's likely a fact of life.
Keep the cash flowing to pay for future opportunities - they will not rush into anything.
Keeping the shelf prospectus available for the future will continue - renew in early 2023 ???
An absolute mirror image of PLB in condensed formation - recognize that and you will not be surprised by anything here. Ignore that and you just won't understand how GUD develops over time.
---------------------------
We have a huge interest in ATE and if you're following, you will know that ATE has recently modified their OTENA formulation by reducing the crystalline structure in that drug - making it more effective in a number of ways ...
- faster onset (better for acute pain)
- lower dosing possible (opens the door to a new chronic pathway for P3 - fingers crossed)
- safer all-around with significantly lower dosing (good for acute and chronic trials)
- likely to update us next week on their next candidate selection for IBD
- the shelf prospectus is likely focused on partnering for OTENA in Latam but only after the bugs are all ironed out and a successful run to P3 is possible (for acute, chronic or both). Failing that direction, they'll find a future opportunity for the shelf prospectus but only at a much higher share price - beyond $10/share
- moving into South-East Asia or Eastern Europe ... likely will be stalled for a while unless an obvious and cost effective opportunity should arise. Focus on LATAM development is the likeliest of scenarios over the next 5 years.
- hmmmmm ... another interesting direction ... Profound will be looking to cash up and GUD might be interested in prostate cancer ablasion in some LATAM regions ... like Brazil ? Could see a deal here as trial data continues to prove TULSA's value as a best-in-class. Note, there is a first Canadian location now at Sunnybrook but mostly for trials and learning purposes - GUD has no interest in taking on the Canadian license until a few thing happen. In Canada, we need to solve the issue with MRI high demand and TULSA's need for MRI in closed-loop operations. Demand for the process will create a need in Canada but only after insurance coverage is properly available. That all takes time. Nothing is simple and that's why patience is needed when building/investing in a ROW.
So much more but we only have limited time in the day.
--------------------
All important considerations going forward.